SGLT2 inhibitor
Dapagliflozin
DAPAGLIFLOZIN
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD 5.70 (3.91 to 7.44) | 0.00 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD 5.77 (3.93 to 7.57) | 0.00 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Exenatide extended release injection | MD 0.15 (-0.83 to 1.12) | 0.45 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.02 (0.44 to 6.15) | 0.21 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.51 (0.40 to 4.30) | 0.13 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.26 (0.00 to 11.30) | 0.56 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.18 (0.00 to 9.49) | 0.56 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.40 (1.14 to 10.03) | 0.37 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.36 (0.00 to 23.95) | 0.65 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.35 (-6.02 to -0.62) | 0.66 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.64 (-5.61 to 0.38) | 0.63 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.65 (-6.08 to 0.88) | 0.48 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.96 (-6.83 to 0.71) | 0.46 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.20 (0.66 to 2.21) | 0.39 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.16 (0.62 to 2.14) | 0.39 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.89 (0.17 to 4.49) | 0.66 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.36 (0.24 to 8.37) | 0.50 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.68 (0.35 to 1.31) | 0.83 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.69 (0.31 to 1.51) | 0.68 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.85 (0.35 to 2.03) | 0.78 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.01 (0.35 to 2.93) | 0.66 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.06 (0.55 to 2.03) | 0.68 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.07 (0.54 to 2.14) | 0.61 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.16 (0.19 to 8.30) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.00 (0.25 to 24.43) | 0.38 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.09 (0.00 to 1.77) | 0.87 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 3.25) | 0.79 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.60 (0.04 to 7.23) | 0.55 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.53 (0.04 to 6.29) | 0.50 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.19 (-0.97 to 0.61) | 0.56 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.18 (-1.04 to 0.67) | 0.47 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -0.01 (-0.23 to 0.20) | 0.40 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD -0.01 (-0.22 to 0.19) | 0.39 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.52 (0.01 to 38.46) | 0.62 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.68 (0.01 to 46.45) | 0.55 |
Trials
- S003425115 randomized · 13.04 weeks
- NCT06589765A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2)2024 · 810 randomized · 52 weeks
- S0030092023 · 88 randomized · 24 weeks
- NCT04451837Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology2020 · 239 randomized · 26.07 weeks
- S0031522019 · 360 randomized · 24 weeks
- NCT02962492An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes2016 · 70 randomized · 12 weeks
- NCT02229396A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin2014 · 695 randomized · 104 weeks